At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
docetaxel + cyclophosphamide + pegfilgrastimdrug
Likely dose
docetaxel + cyclophosphamide + pegfilgrastim 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer
In Brief
A Phase 2 clinical trial evaluating docetaxel + cyclophosphamide + pegfilgrastim for Female Breast Cancer. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the feasibility of giving standard TC chemotherapy on a dose dense schedule (ddTC) as well as evaluating the nature and frequency of ddTC side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFemale Breast Cancer
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedAug 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedAug 23, 2012
Enrollment StartJun 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.9 years ago
Interventions
docetaxel + cyclophosphamide + pegfilgrastimdrug
docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle